Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.

http://www.marketwatch.com/story/novartis-licenses-hepatitis-c-drug-2010-02-09

This entry was posted on Wednesday, February 10th, 2010 at 10:18 AM and is filed under Research & Development. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.